胸腺基质淋巴细胞生成素
哮喘
医学
免疫学
不利影响
单克隆抗体
药理学
抗体
作者
Paola Rogliani,G Manzetti,Federica Roberta Bettin,M.V. D’Auria,Luigino Calzetta
标识
DOI:10.1080/13543784.2024.2305144
摘要
Introduction Severe asthma patients often remain uncontrolled despite high-intensity therapies. Biological therapies targeting thymic stromal lymphopoietin (TSLP), a key player in asthma pathogenesis, have emerged as potential options. Currently, the only TSLP inhibitor approved for the treatment of severe asthma is the immunoglobulin G (IgG) 2λ anti-TSLP monoclonal antibody (mAb) tezepelumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI